Chief Science Advisor (Canada)

IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team

Retrieved on: 
Wednesday, November 15, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Acquisition, Food, Data science, Biology, Takeda, Patient, Immune-mediated inflammatory diseases, Medicine, Informatics, Chief Science Advisor (Canada), Artificial intelligence, Intelligence, Machine learning, Digital, IMID, Biomedical Research, Digital technology, Drug discovery, Digital Insight, QIAGEN Silicon Valley, Knowledge, QIAGEN, Public, Datavant, J&J, Medical device, Immunotherapy

In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science.

Key Points: 
  • In addition, Dr. Ramon Felciano, joins as a strategic advisor in biomedical artificial intelligence and data science.
  • These additions will play a pivotal role in advancing IMIDomics' mission to accelerate data-driven drug discovery and development aimed at treating IMID patients.
  • Dr. Perakslis brings over two decades of experience in research, digital innovation, data science and technology leadership to IMIDomics.
  • With Eric and Ramon on board, we are confident in our ability to expedite the pace of discovery and innovation at IMIDomics."

Cyclica Recruits Big Pharma Veteran Michael Palovich as Chief Science Officer to Advance Robust Drug Discovery Pipeline

Retrieved on: 
Tuesday, February 1, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Believer, Entrepreneurship, CEO, Drug discovery, Degenerative disease, Patient, AI, Chief Science Advisor (Canada), Bromide, Drive Capital, GSK, Disease, Inc., Pleasure, GlaxoSmithKline, Pharmaceutical industry, Cyclica

Cyclica Inc. (Cyclica), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery.

Key Points: 
  • Cyclica Inc. (Cyclica), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery.
  • Mike brings 24 years of drug discovery experience at GlaxoSmithKline (GSK), where he led drug discovery programs spanning multiple therapeutic areas with a highly successful track record.
  • In his role at Cyclica, Mike will lead a growing team of drug discovery scientists who are advancing a sustainable pipeline of therapeutically rich and diverse assets.
  • Palovich shares Kurjis sentiment about his anticipated contribution as the Chief Science Officer: Im looking forward to collaborating with the innovative team at Cyclica to drive their robust pipeline forward.